Prevention and management of adverse effects of disease modifying treatments in multiple sclerosis

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Multiple sclerosis (MS) treatments have advanced significantly, introducing highly effective therapies.
• Real-world application reveals side effects not always apparent in shorter clinical trials.
• Patient heterogeneity in real-world settings (comorbidities, age, prior treatments) influences side effect profiles.

Purpose of the Study:

• To compile known side effects associated with approved multiple sclerosis therapies.
• To propose essential monitoring protocols for patients undergoing MS treatment.

Main Methods:

• Review of approved multiple sclerosis therapies and their documented side effects.
• Analysis of side effect data from clinical trials and real-world evidence.
• Synthesis of monitoring recommendations based on identified risks.

Main Results:

• Approved MS therapies present a spectrum of side effects, from mild infections and laboratory abnormalities to severe conditions like progressive multifocal leukoencephalopathy (PML) and secondary autoimmune diseases.
• Side effects can manifest during or after treatment initiation.
• The real-world patient population exhibits a wider range of responses and potential adverse events compared to controlled study groups.

Conclusions:

• Neurologists must remain vigilant for both known and emerging side effects of MS therapies.
• A careful balance of therapeutic benefits against potential risks is essential.
• Continuous monitoring and awareness are critical for managing multiple sclerosis effectively and ensuring patient safety.